3.08 Racial Concordance in Birthing Mortality & HERO for Journal Club with Fellow Dr. Michael Burns

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7 • 789 Ratings

🗓️ 22 August 2020

⏱️ 93 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

This week we take a deep dive into two recently published studies, their surrounding controversy, and the broader implications. The first study was published in the journal Proceedings of the National Academy of Sciences of the USA and is titled "Physician–patient racial concordance and disparities in birthing mortality for newborns". The second was published in the New England Journal of Medicine and is titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer", commonly known as the HERO trial. We discuss the HERO trial with Dr. Michael Burns of Northwestern as part of our new segment, Journal Club with a Fellow. Racial Concordance: doi.org/10.1073/pnas.1913405117 HERO: doi.org/10.1056/NEJMoa2004325 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome. I'm Dr. Vinay Prasad. I'm a hematologist, oncologist, and I'm associate professor of medicine at the University of California, San Francisco. In my professional life, I see patients, I teach trainees, and I do research in health care policy. This is plenary session. Plenary session is a
0:24.0	podcast at the intersection of medicine, oncology, and health policy, and you're listening to
0:28.5	season three. On this week's episode, I'm joined via Zoom by Dr. Michael Burns. He's a physician scientist
0:37.0	and hemong fellow at Northwestern University, and he is the second
0:40.1	trainee to come here for Journal Club with the trainee.
0:42.9	We're going to talk about the Hero's Study.
0:44.7	This is a randomized controlled trial of Ruluglix, which is an oral G&RH antagonist.
0:50.9	And I don't know if I pronounce that correctly, but by the end of this podcast,
0:54.4	you're going to know the truth. I don't need to pronounce it correctly because this is a drug
0:57.9	that's not going to get much use. So stay tuned for that great discussion. It really makes one
1:02.8	think of that quote. You either die a hero or live long enough to become the villain.
1:07.4	But first, I'm going to talk about a new paper that came out in PNAS. This is a paper that I
1:12.0	believe is on a very important issue, an issue that we need to do a lot of societal reflecting
1:17.4	about, but it's a paper that has some structural and methodologic problems, and I want to separate
1:21.4	these two things, how we can both be devoted to important causes, but also be appropriately critical of information
1:29.5	that may not prove what the authors believe they have proved. So that's what you're going to get
1:33.8	on this week's plenary session.
1:40.6	If you like this podcast and want more content, follow me on Twitter at Viprasad MDMPH.
1:47.1	Check out the YouTube channel, Vinay Prasad, MDMPH.
1:51.3	Patreon backers will get access to the slides for lectures I give on plenary session.
1:55.9	Want to hear from us?
1:57.1	Email us your question at plenary session podcast at gmail.com.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.